Tumor necrosis factor (TNF) is an inflammatory cytokine that has important roles in various immune responses, which are mediated through its two receptors, TNF receptor 1 (TNFR1) and TNFR2. Antibody-based therapy against TNF is used clinically to treat several chronic autoimmune diseases; however, such treatment sometimes results in serious side effects, which are thought to be caused by the blocking of signals from both TNFRs. Therefore, knowledge of the structural basis for the recognition of TNF by each receptor would be invaluable in designing TNFR-selective drugs. Here, we solved the 3.0 angstrom resolution structure of the TNF-TNFR2 complex, which provided insight into the molecular recognition of TNF by TNFR2. Comparison to the known TNFR1 structure highlighted several differences between the ligand-binding interfaces of the two receptors. Additionally, we also demonstrated that TNF-TNFR2 formed aggregates on the surface of cells, which may be required for signal initiation. These results may contribute to the design of therapeutics for autoimmune diseases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1126/scisignal.2000954 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Usenamine A: a potential therapeutic agent for rheumatoid arthritis and ankylosing spondylitis through its anti-inflammatory activity.
Front Pharmacol
December 2024
Department of Biomedical Sciences, Graduate School of Chonnam National University, Jeollanam-do, Republic of Korea.
Background: Usenamine A (UA) is a natural compound isolated from the lichen , and its therapeutic effects on rheumatic diseases are not well understood. This study aimed to evaluate the potential anti-inflammatory effects of UA and its therapeutic effects on rheumatoid arthritis (RA) and ankylosing spondylitis (AS).
Materials And Methods: Molecular docking was performed between the 3D structure of UA and the TNF-TNFR2 complex.
[Functional Study of TNFR2 Signaling and Drug Discovery Using a Protein Engineering Approach].
Yakugaku Zasshi
December 2022
Faculty of Pharmaceutical Sciences, Kobe Gakuin University.
Tumor necrosis factor-α (TNF), a proinflammatory cytokine, is critical to the pathogenesis of various inflammatory diseases. There are two subtypes of receptors for TNF, namely type I TNF receptor (TNFR1) and type II TNF receptor (TNFR2). Previous studies using animal models of diseases have demonstrated the predominant role of TNFR1 in the pathogenesis of inflammation.
View Article and Find Full Text PDFSensory Ganglia-Specific TNF Expression Is Associated With Persistent Nociception After Resolution of Inflammation.
Front Immunol
November 2020
Departamento de Morfologia, Instituto de Ciências Biológicas (ICB), Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil.
Joint pain is a distressing symptom of arthritis, and it is frequently persistent even after treatments which reduce local inflammation. Continuous production of algogenic factors activate/sensitize nociceptors in the joint structures and contribute to persistent pain, a challenging and difficult condition to treat. TNF is a crucial cytokine for the pathogenesis of several rheumatic diseases, and its inhibition is a mainstay of treatment to control joint symptoms, including pain.
View Article and Find Full Text PDFTNF Receptor Type II as an Emerging Drug Target for the Treatment of Cancer, Autoimmune Diseases, and Graft-Versus-Host Disease: Current Perspectives and Search for Small Molecule Binders.
Front Immunol
June 2018
Department of Computer and Information Science, Faculty of Science and Technology, University of Macau, Macao, China.
There is now compelling evidence that TNF receptor type II (TNFR2) is predominantly expressed on CD4Foxp3 regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), and plays a major role in the expansion and function of Tregs and MDSCs. Consequently, targeting of TNFR2 by either antagonists or agonists may represent a novel strategy in the treatment of cancer and autoimmune diseases, by downregulating or upregulating suppressor cell activity. The advance in the understanding of complex structure of TNFR2 and its binding with TNF at molecular levels offers opportunity for structure-guided drug discovery.
View Article and Find Full Text PDFStructure of the human aminopeptidase XPNPEP3 and comparison of its activity with Icp55 orthologs: Insights into diverse cellular processes.
J Biol Chem
June 2017
From the High Pressure and Synchrotron Radiation Physics Division and
The human aminopeptidase XPNPEP3 is associated with cystic kidney disease and TNF-TNFR2 cellular signaling. Its yeast and plant homolog Icp55 processes several imported mitochondrial matrix proteins leading to their stabilization. However, the molecular basis for the diverse roles of these enzymes in the cell is unknown.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!